Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Up 16,004.0% in December

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 801,174 shares, an increase of 16,004.0% from the December 15th total of 4,975 shares. Approximately 0.2% of the company’s shares are sold short. Based on an average daily volume of 642,736 shares, the short-interest ratio is presently 1.2 days. Based on an average daily volume of 642,736 shares, the short-interest ratio is presently 1.2 days. Approximately 0.2% of the company’s shares are sold short.

Provectus Biopharmaceuticals Stock Down 0.3%

Shares of Provectus Biopharmaceuticals stock opened at $0.06 on Tuesday. The stock’s fifty day simple moving average is $0.06 and its 200 day simple moving average is $0.07. Provectus Biopharmaceuticals has a 12 month low of $0.05 and a 12 month high of $0.12.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc is a U.S.-based clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology and tumor ablation therapies. Headquartered in Knoxville, Tennessee, the company’s lead investigational product is PV-10, a proprietary formulation of Rose Bengal disodium for intralesional injection. PV-10 is designed to selectively ablate tumor cells while stimulating a systemic immune response against cancerous lesions.

PV-10 has been evaluated in multiple clinical trials across a range of solid tumors, with key studies conducted in melanoma, hepatocellular carcinoma and other refractory cancers.